Syros Pharmaceuticals, Inc. (OTC:SYRS) Q2 2024 Earnings Conference Call July 31, 2024 8:30 AM ET
Company Participants
Karen Hunady - Director of Investor Relations and Corporate Communications
Conley Chee - President and Chief Executive Officer
David Roth - Chief Medical Officer
Jason Haas - Chief Financial Officer
Conference Call Participants
Philip Nadeau - TD Cowen
Ted Tenthoff - Piper Sandler
Roy Buchanan - Citizens JMP
Leah Cann - Brookline Capital Markets
Operator
Good morning, and welcome to Syros Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors & Media section of Syros website at www.syros.com. Please be advised that today's call is being recorded.
At this time, I would like to turn the call over to Karen Hunady, Director of Investor Relations and Corporate Communications at Syros. Please go ahead.
Karen Hunady
Thank you. This morning, we issued a press release announcing our second quarter 2024 financial results. The full release is available on the Investor & Media section of Syros' website at www.syros.com.
We will begin the call with prepared remarks by Conley Chee, our Chief Executive Officer; Dr. David Roth, our Chief Medical Officer; and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Kristin Stephens, our Chief Development Officer, is also here on the call with us and will be available for Q&A.
Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed, or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section, of our quarterly report on Form 10-Q that we filed this
- Read more current SYRS analysis and news
- View all earnings call transcripts